Skip to content

Effect of remazolam tosylate and dexmedetomidine on the quality of anesthesia revival in patients on single-lung ventilation

Effect of remazolam and dexmedetomidine on the quality of anesthesia revival in patients on single-lung ventilation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074617
Enrollment
Unknown
Registered
2023-08-10
Start date
2022-08-30
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung tumors

Interventions

Remazolam tosylate group:During the anesthesia maintenance period, from the start of skin incision to the end of surgery, continue to pump 0.2mg/kg/h of remazolam tosylate
Dexmedetomidine group:During the anesthesia maintenance period, continue to pump 0.4 ug/kg/h of dexmedetomidine from the start of skin incision to the end of surgery

Sponsors

The First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA grade II.-III., cardiac function I.-II.; Patients who undergo single-lung ventilation with thoracotomy under elective general anesthesia; No obvious cardiovascular, lung, liver, kidney and other important organ diseases, no electrolyte imbalances and infections, no immune and endocrine system diseases; have not taken nonsteroidal anti-inflammatory drugs and hormonal drugs in the near future, and have not received other drug studies in the month before surgery; After pulmonary function training before surgery, lung function is within normal levels; Estimated duration of surgery is 4-6 hours.

Exclusion criteria

Exclusion criteria: Immune, endocrine, neurological and psychiatric disorders before surgery; Severe heart, lung, liver, and kidney dysfunction; narrowing or occlusion of one or both main bronchi due to lung disorders or other diseases; preoperative use of immunosuppressive drugs and nonsteroidal anti-inflammatory drugs; Respiratory and pulmonary infections before surgery; Forced expiratory volume (FEV1) in the first second of preoperative pulmonary function test 30mmHg; Intraoperative oxygen saturation is continuously less than 90%, and airway pressure > 40cmH2O; Intraoperative persistent hypotension or hypertension, mean arterial pressure is less than or above the basal value of 20%, intraoperative blood loss is greater than 1000ml.

Design outcomes

Primary

MeasureTime frame
Average arterial pressure, heart rate, blood oxygen saturation,Respiratory rate,Aldrete score;

Secondary

MeasureTime frame
Sufentanil use, propofol use, operation time, single lung ventilation time, anesthesia recovery room stay;Complications of anesthesia;

Countries

China

Contacts

Public ContactWang Dan

The First Affiliated Hospital of Harbin Medical University

wang_dan1980@126.com+86 183 4517 7888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026